Big pharma company Bayer , is going hunting for pharma deals again, with its chief executive expected to tell media outlets that it is looking for further takeover pharma deals.
"We are looking to expand our business in the future through both organic growth and acquisitions," CEO Marijn Dekkers is slated to say in a speech to during the company’s third quarter results reporting on Thursday. News outlets received a copy of the speech ahead of time.
Bayer snapped up Merck & Co. Inc.'s consumer health business earlier this year for $14.2 billion.
“This acquisition marks a major milestone on our path towards global leadership in the attractive non-prescription medicines business," said Dekkers at the time. “At the same time we are leveraging our capabilities in the cardiovascular therapeutic area.”
For further pharma deals information visit Current Agreements (subscription required)
View: Partnering Scorecard in CP Insight– view top life science partnering deals by value
View: DealMetrics in CP Insight – the latest deal trend infographics for life science deal making
View: CP Insight’s Big Pharma Deal Making Scorecard – latest trends in big pharma deal making activity
View: CP Insight’s Big Biotech Deal Making Scorecard – latest trends in big biotech deal making activity